Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BAY1082439 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Arm 1 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| BAY1082439 | DRUG | BAY1082439 will be given orally once daily with a 21 days cycle. Dose will be started from 15mg. |
Inclusion Criteria: * Subjects with advanced, histologically or cytologically confirmed solid tumors, refractory to any standard therapy, have no standard therapy available, or subjects must have actively refused any treatment which would be regarded standard, and / or if in the judgment of the inv...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Bristol-Myers Squibb Company | BMY | 5 | PHASE3 | ACE-536 |
| AbbVie, Inc. | ABBV | 4 | PHASE3 | Navitoclax, Ruxolitinib |
| Novartis AG Sponsored ADR | NVS | 3 | PHASE3 | Pelabresib, Ruxolitinib |
| Karyopharm Therapeutics, Inc. | KPTI | 4 | PHASE3 | Selinexor, Ruxolitinib |
| Geron Corporation | GERN | 2 | PHASE3 | Imetelstat |
| Merck & Co., Inc. | MRK | 1 | PHASE3 | Bomedemstat |
| Incyte Corporation | INCY | 10 | PHASE2 | Ruxolitinib |
| GSK plc Sponsored ADR | GSK | 2 | PHASE2 | MMB |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 1 | PHASE2 | Elritercept, Ruxolitinib |
| Eli Lilly and Company | LLY | 1 | PHASE1 | LY3410738, Venetoclax, Azacitidine |
| Disc Medicine, Inc. | IRON | 1 | PHASE1 | DISC-0974 |
| Galecto, Inc. | GLTO | 1 | PHASE2 | GB2064 |
| Prelude Therapeutics, Inc. | PRLD | 1 | PHASE1 | PRT12396 |
| United Therapeutics Corporation | UTHR | 1 | PHASE2 | bomedemstat |
BAY1082439 is an investigational small molecule being studied for the treatment of neoplasms, which are abnormal growths of tissue that can be benign or malignant. It is currently in clinical development for oncology indications, specifically in patients with advanced cancer.
BAY1082439 is being developed by Bayer AG, a multinational pharmaceutical company headquartered in Germany. Bayer's stock is traded on the OTC market under the ticker symbol BAYRY.
BAY1082439 is in Phase 1 clinical development. It is an investigational drug that has not yet been approved by regulatory authorities. The drug is being studied in an early-stage clinical trial to evaluate its safety and tolerability in patients with advanced cancer.
BAY1082439 has been studied in one clinical trial with the identifier NCT01728311, titled 'Open Label Study of BAY1082439 in Patients With Advanced Cancer.' This Phase 1 trial enrolled 60 participants and was conducted in Singapore, South Korea, and Taiwan. The trial has been completed.
The specific molecular target of BAY1082439 has not been disclosed in available information. As a small molecule, it is designed to interact with cellular components to exert its therapeutic effect, but the exact mechanism of action is not publicly detailed.